Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2006

01-04-2006 | Original Article

Cancer patients’ first treatment episode with opioids: a pharmaco-epidemiological perspective

Authors: Lene Jarlbaek, Jesper Hallas, Jakob Kragstrup, Morten Andersen

Published in: Supportive Care in Cancer | Issue 4/2006

Login to get access

Abstract

Goal

The factors underlying the choice of opioids for cancer patients in primary care are largely unknown. Our aim was to describe cancer patients’ first treatment episode with opioids in relation to disease characteristics and clinical course.

Patients and methods

During 1997 and 1998, a population-based cohort of 4,006 incident cancer patients from a Danish county was identified. The patients were followed up from diagnosis to death or until 31 December 2003, and data on their use of opioids were obtained from a prescription database.

Main results

Eventually, 54% of the cancer patients became incident users of opioids. Opioid treatment was initiated close to the diagnosis date in 20% of the patients. Most incident users (57%) were not terminal when they began using opioids, and 44% survived the first treatment episode. Of those who died, 70% received opioids in their terminal phase. The incidence rates of new opioid users were inversely related to the 5-year cancer survival period. A weak opioid was the first choice in 64% of the non-terminal users and in 43% of the terminal ones. No statistically significant differences in opioid use were found between men and women.

Conclusions

Opioid use in cancer patients was not confined to the terminal course. Treatment with opioids should be viewed as a dynamic condition, with patients shifting between periods of use and non-use. The aggressiveness of the cancer and the presence of metastases were characteristics found to be strong determinants of opioid use.
Literature
1.
Ahmedzai SH, Costa A, Blengini C, Bosch A, Sanz-Ortiz J, Ventafridda V et al (2004) A new international framework for palliative care. Eur J Cancer 40(15):2192–2200PubMedCrossRef
2.
Brema F, Pastorino G, Martini MC, Gottlieb A, Luzzani M, Libretti A et al (1996) Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 16(4–5):109–116PubMed
3.
Capocaccia R, Colonna M, Corazziari I, De Angelis R, Francisci S, Micheli A et al (2002) Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 13(6):831–839PubMedCrossRef
4.
Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA et al (1994) Pain and its treatment in outpatients with metastatic cancer (see comments). N Engl J Med 330(9):592–596PubMedCrossRef
5.
Dalton JA, Youngblood R (2000) Clinical application of the World Health Organization analgesic ladder. J Intraven Nurs 23(2):118–124PubMed
6.
7.
8.
Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D et al (2004) No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage 28(3):225–232PubMedCrossRef
9.
Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44(4):445–448PubMed
10.
Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195PubMedCrossRef
11.
Goudas L, Carr DB, Bloch R (2001) Management of cancer pain. Evidence Report/Technology Assessment No. 35 (Prepared by the New England Medical Center Evidence-based Practice Center under Contract No 290-97-0019). AHRQ Publication No. 02-E002. Agency for Healthcare Research and Quality, Rockville, MD. October 2001. http://​www.​ahrq.​gov/​clinic/​epcsums/​canpainsum.​htm. Cited 2001
12.
13.
Grond S, Meuser T (1998) Weak opioids—an educational substitute for morphine? Curr Opin Anaesthesiol 11(5):559–565PubMedCrossRef
14.
Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 18(3):174–179PubMedCrossRef
15.
Hallas J (2001) Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 10(7):619–623PubMedCrossRef
16.
Jarlbaek L, Andersen M, Kragstrup J, Hallas J (2004) Cancer patients’ share in a population’s use of opioids: A linkage study between a prescription database and the Danish Cancer Registry. J Pain Symptom Manage 27(1):36–43PubMedCrossRef
17.
Jarlbaek L, Andersen M, Hallas J, Engholm G, Kragstrup J (2005) Use of opioids in a Danish population-based cohort of cancer patients. J Pain Symptom Manage 29(4):336–343PubMedCrossRef
18.
Keogh E, Arendt-Nielsen L (2004) Sex differences in pain. Eur J Pain 8(5):395–396CrossRef
19.
Levy MH (1996) Pharmacologic treatment of cancer pain (see comments). N Engl J Med 335(15):1124–1132PubMedCrossRef
20.
Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A et al (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27(5):409–416PubMedCrossRef
21.
Merrill RM, Capocaccia R, Feuer EJ, Mariotto A (2000) Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program. Int J Epidemiol 29(2):197–207PubMedCrossRef
22.
Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A (2001) Slow-release tramadol for treatment of chronic malignant pain—an open multicenter trial. Support Care Cancer 9(1):48–54PubMed
23.
24.
Rostgaard K, Holst H, Mouridsen HT, Lynge E (2000) Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark. Cancer Causes Control 11(7):669–674PubMedCrossRef
25.
Sjogren P, Banning AM, Jensen NH, Jensen M, Klee M, Vainio A (1996) Management of cancer pain in Denmark: a nationwide questionnaire survey. Pain 64(3):519–525PubMedCrossRef
26.
Stata. Release 7.0 and 8.0, 2001 and 2003, StataCorp. Stata Statistical Software (2001, 2003). Stata Corporation, College Station, TX
27.
Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry—history, content, quality and use. Dan Med Bull 44(5):535–539PubMed
28.
Turk DC, Okifuji A (1999) Does sex make a difference in the prescription of treatments and the adaptation to chronic pain by cancer and non-cancer patients? Pain 82(2):139–148PubMedCrossRef
29.
30.
Vainio A (1998) Use of morphine and other opioids in the Nordic countries. Acta Oncol 37(7–8):743–748PubMedCrossRef
31.
WHO (1996) Cancer pain relief. With a guide to opioid availability, 2nd ed. WHO
32.
WHO Collaborating Centre for Drug Statistics Methodology (2002) Guidelines for ATC classification and DDD assignment 2002, 5th ed.
Metadata
Title
Cancer patients’ first treatment episode with opioids: a pharmaco-epidemiological perspective
Authors
Lene Jarlbaek
Jesper Hallas
Jakob Kragstrup
Morten Andersen
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0890-8

Other articles of this Issue 4/2006

Supportive Care in Cancer 4/2006 Go to the issue

Editorial

Communication and phase 1 clinical trial recruitment

Original Article

Quality of life in terminal care—with special reference to age, gender and marital status

Original Article

EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units

Original Article

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Short Communication

Gabapentin in the treatment of severe sweating experienced by advanced cancer patients

Original Article

An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits